Why disease setting changes the timing question
Timing starts with the treatment goal and confirmed disease extent, rather than an automatic sequence of ablation, SBRT (stereotactic body radiation therapy) and radioligands.
Before you start: Local injury describes mechanisms. ctDNA and MRD explains why blood detection and visible lesions differ.
Define the goal first
Local treatment may aim to relieve pain, protect an organ, control a selected growing lesion or contribute to a curative plan in an established setting. Investigational immune priming is a different goal. Combining those goals in one sentence can make experimental benefit sound like standard care.
Neoadjuvant treatment occurs before surgery; adjuvant treatment follows it. Oligometastatic disease means a limited metastatic burden under a specified definition. Oligoprogression means a limited number of sites progress while other disease remains controlled. Definitions and permitted lesion counts vary by study.
A preoperative immune-priming study, postoperative breast radiation and local therapy for metastatic progression ask different questions. Results from one do not define the timing of another.
A blood result does not define anatomy
A positive circulating tumor DNA (ctDNA) result can precede radiographic recurrence in a cohort. The lead time varies and is not a guaranteed treatment window. Some tumors shed little DNA; some ctDNA-positive patients already have metastases when staged. The c-TRAK TN experience illustrates this limitation.
The result leads to assessment, rather than directly to a procedure.
Blood does not specify where to put a probe or aim a radiation plan. A negative result does not exclude a known lesion. Earlier detection alone does not establish that earlier intervention improves survival; lead-time bias can lengthen measured survival from diagnosis without delaying death.
Different tools have different clocks
| Tool | Planning questions | Timing constraint |
|---|---|---|
| Ablation | Can the lesion and an adequate margin be safely reached? | Organ recovery, bleeding risk, anesthesia and nearby anatomy |
| Stereotactic body radiotherapy (SBRT) | What volume, motion and cumulative normal-organ dose must be covered? | Planning, fraction schedule and prior radiation |
| Radioligand therapy | Which exact ligand, indication, uptake evidence and dosimetry apply? | Product/protocol schedule, marrow and organ reserve |
| A combination with checkpoint inhibition | Does this sequence have relevant evidence and acceptable safety? | Protocol-defined timing; prior toxicity and exposure |
No fixed “repeat every few weeks” or “no cumulative injury” rule applies to every ablation. Radioligand cycles also vary by product and study. Scheduling must come from the actual plan, rather than a modality label.
A worked comparison
One patient needs relief from a painful bone lesion. Another has an isolated progressing lesion while systemic therapy controls other sites. A third has molecular positivity without an imageable target. Even if their blood results match, their local-treatment questions do not. The first has a symptom-control goal; the second needs a disease-setting-specific local/systemic review; the third lacks a local target.
Prior checkpoint exposure matters. Progression during checkpoint treatment differs from checkpoint-naive disease. A history of pneumonitis adds a safety question independent of a proposed immune-priming mechanism. Having received pembrolizumab earlier does not mean it remains “on board” or is safe to restart.
Try it
A ctDNA-positive result appears, but imaging finds no target. Does a three-centimeter ablation threshold select treatment?
Answer: No. There is no defined lesion to measure or treat, and a local-size rule cannot choose systemic care.
Explain it back: “The goal, extent of disease and treatment history define the timing question.”
Explain it back
Establish the setting before choosing a clock or a tool.
Takeaway
Establish the setting before choosing a clock or a tool.
Next: Read combination evidence.
Vocabulary: MRD means molecular residual disease.
Sources and scope
General teaching, source-checked October 8, 2026. Expert and learner review remain pending. These lessons explain mechanisms and study interpretation; current choices are owned by the care plan and the local-priming question.